[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer.
Sharma R, Valls PO, Inglese M, Dubash S, Chen M, Gabra H, Montes A, Challapalli A, Arshad M, Tharakan G, Chambers E, Cole T, Lozano-Kuehne JP, Barwick TD, Aboagye EO.
Sharma R, et al. Among authors: aboagye eo.
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1239-1251. doi: 10.1007/s00259-019-04532-z. Epub 2019 Nov 21.
Eur J Nucl Med Mol Imaging. 2020.
PMID: 31754793
Free PMC article.
Clinical Trial.